
Helus Pharma rose 46.1% from $6.07 to $8.87, ahead of the S&P 500's +13.3%. Its worst day was Mar 5 (−33.9%), and its low came Jun 10 at $3.87.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.00 missed the $-0.80 estimate on $0.00 revenue.
+2.9% · S&P 500 +0.1%
Helus Pharma shares fell 33.9%, while the S&P 500 fell 0.6%.
Story events cover the past 12 months · Times ET
−33.9%, the year's worst day, on 9M shares, the year's heaviest volume · S&P 500 −0.6%
Helus Pharma shares rose 17.0%, while the S&P 500 rose 1.0%.
+17.0% · S&P 500 +1.0%
Helus Pharma closed at its lowest level of the year, 36.2% below where the year started.
−1.3% · S&P 500 −1.6%
EPS of $-0.85 beat the $-1.11 estimate on $0.00 revenue.
+6.2% · S&P 500 +1.6%
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataHLP003 previously
+13.9% · S&P 500 +0.8%
Helus Pharma shares rose 15.1%, while the S&P 500 rose 1.8%.
+15.1% · S&P 500 +1.8%
EPS of $-0.91 beat the $-1.07 estimate on $0.00 revenue.
+4.7% · S&P 500 −0.2%
Helus Pharma closed at its highest level of the year, 131.0% above where the year started.
+4.1% · S&P 500 +0.9%
Helus Pharma shares fell 16.9%, while the S&P 500 fell 0.5%.
−16.9% · S&P 500 −0.5%
Where it ended: a close of $8.87 on Nov 13, 2026. Up next: Q2 2026 earnings on Nov 27, 2026 (EPS est. $-0.67).
Nothing in the past 12 months.
All HELP dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HELP and SPY from Benzinga historical bars. Not investment advice.